Progression of Disease Within 24 Months in Follicular Lymphoma Is ...

Assessment of immune-infiltration by PD-L2 expression is a promising tool with which to help identify patients who are at risk for POD24.

Understanding the immunobiology of the 15% to 30% of patients with follicular lymphoma (FL) who experience progression of disease within 24 ...

Progression of disease within 24 months (POD24) in follicular ...

Follicular lymphoma (FL) is a lymphoproliferative neoplasia typically considered incurable. It is most often characterized by a slow, indolent ...

Prognosis of Progressive Follicular Lymphoma within 24 Months of ...

Progression of follicular lymphoma (FL) within 24 months of initiating first-line therapy (POD24) is a strong driver of poor outcomes and is ...

Progression of Follicular Lymphoma within 24 Months of First ...

Background: Follicular lymphoma (FL) is the most common indolent lymphoma in the western world with a median survival approaching 20 years.

Survival by First-line Treatment Type and Timing of Progression

In follicular lymphoma (FL), progression of disease ≤24 months (POD24) has emerged as an important prognostic marker for overall survival (OS).

Time for an individualized approach to first-line management of ...

Patients experiencing disease progression within 24 months after treatment initiation (POD24) represent a particular group of need, with a 5 ...

Relapsed Follicular Lymphoma With POD 24 - The ASCO Post

... lymphoma who experience progression of disease within 24 months (POD-24). The patient is a 71-year-old fit, White man who presented with ...

Predicting early progression in follicular lymphoma - Liu

Recent evidence has demonstrated that 10–20% of patients who are treated with immunochemotherapy experience relapse within 24 months of diagnosis and these ...

Follicular Lymphoma Management Overview - Medscape Reference

... follicular lymphoma do not require hospitalization during the early stages of the disease. ... Relapse of follicular lymphoma within 24 months ...

How I treat early-relapsing follicular lymphoma - ScienceDirect

Relapse of FL within 24 months of chemoimmunotherapy (POD24) is now established as a robust marker of poor survival, leading to increased risk ...

Follicular Lymphoma: Progression of Disease - OncLive

... [progression of disease] of those people who are progressing within 24 months. So in all-comers, it's hard for me to predict. It's often why ...

REVIEW Advancements in the Management of Follicular Lymphoma

The most consistent predictor of OS in FL patients is progression of the disease within 24 months (POD-24) of initial therapy. After RCHOP treatment, the 5-year ...

Follicular Lymphoma: a Focus on Current and Emerging Therapies

Approximately 20% of patients have early relapse and progression of disease within 24 months (POD24), and these patients have poor outcomes.

Association of early disease progression and very poor survival in ...

Early disease progression in patients with follicular lymphoma was associated with poor prognosis, with mortality risk higher after earlier progression.

Follicular lymphoma: 2023 update on diagnosis and management

Overall, 1-year PFS was 67% but was 86% for patients who had a CR. Progression of disease within 24 months of prior therapy, high metabolic ...

Management of relapsed follicular lymphoma - Rodgers

Unfortunately, most FL patients will experience disease relapse, though usually after a prolonged progression-free survival (PFS) with initial therapy. When a ...

Early Relapse of Follicular Lymphoma After Rituximab Plus ...

Twenty percent of patients with follicular lymphoma (FL) experience progression of disease (POD) within 2 years of initial chemoimmunotherapy.

Progression of Disease Within 24 Months in Follicular Lymphoma Is ...

Purpose: Understanding the immunobiology of the 15% to 30% of patients with follicular lymphoma (FL) who experience progression of disease ...

Impact of early relapse within 24 months after first-line systemic ...

Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior ...